IntelliPharmaCeutics International (IntelliPharmaCeutics International) Debt-to-EBITDA : -0.32 (As of Aug. 2023)

IntelliPharmaCeutics International Debt-to-EBITDA Chart

IntelliPharmaCeutics International Annual Data
	Trend	Nov13	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22
Debt-to-EBITDA		Get a 7-Day Free Trial					-0.14	-0.26	-1.07	-0.43	-0.97

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Debt-to-EBITDA	Get a 7-Day Free Trial															-2.61	-0.77	-2.18	14.76	-0.32

Competitive Comparison of IntelliPharmaCeutics International's Debt-to-EBITDA

For the Biotechnology subindustry, IntelliPharmaCeutics International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Debt-to-EBITDA falls into.

IntelliPharmaCeutics International Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

IntelliPharmaCeutics International's Debt-to-EBITDA for the fiscal year that ended in Nov. 2022 is calculated as

IntelliPharmaCeutics International's annualized Debt-to-EBITDA for the quarter that ended in Aug. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Aug. 2023) EBITDA data.

IntelliPharmaCeutics International  (OTCPK:IPCIF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

IntelliPharmaCeutics International Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description